Scarica l'app Stockscreener
17.92
0.73%
0.13
Dopo l'orario di chiusura:
17.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Travere therapeutics executive sells shares worth $106,081 - MSN
Technical Models Suggest Travere Therapeutics Inc. May Rebound Soon - beatles.ru
Strategic Positioning and Growth Potential Drive Buy Rating for Travere Therapeutics - TipRanks
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN
Travere Therapeutics Inc. Charts Flash Early Recovery SignalsJuly 2025 Levels & Technical Buy Zone Confirmation - metal.it
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Wall Street Zen Upgrades Travere Therapeutics (NASDAQ:TVTX) to Buy - Defense World
How high can Travere Therapeutics Inc. stock goWeekly Trend Recap & High Conviction Buy Zone Picks - Newser
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc.Market Sentiment Report & Real-Time Volume Analysis Alerts - sundaytimes.kr
Is Travere Therapeutics Inc.’s growth already priced inWeekly Trade Summary & Free Safe Capital Growth Stock Tips - thegnnews.com
Multi asset correlation models including Travere Therapeutics Inc.2025 Key Highlights & Weekly High Return Opportunities - Newser
Key metrics from Travere Therapeutics Inc.’s quarterly dataJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Analysts' Top Picks in Healthcare: Merus, AdaptHealth, and Travere Therapeutics - AInvest
Why Travere Therapeutics Inc. is moving todayWeekly Profit Report & Reliable Volume Spike Trade Alerts - Newser
Visualizing Travere Therapeutics Inc. stock with heatmaps2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Travere Therapeutics at Canaccord Genuity: Strategic Insights from Growth Conference - Investing.com Canada
Travere Therapeutics Receives Positive Growth Outlook from Analysts Amid Filspari's Promising Market Potential and Strategic Initiatives - AInvest
Travere Therapeutics Approves Inducement Equity Grants for New Employees - AInvest
Trendlines Converge — Decision Point for Travere Therapeutics Inc.Earnings Performance Report & Entry Point Confirmation Alerts - beatles.ru
Why Travere Therapeutics Inc. stock attracts strong analyst attention2025 Year in Review & Long-Term Capital Growth Ideas - Newser
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc. [Weekly Risk Report]Free Verified Swing Trading Watchlist - 선데이타임즈
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript - MSN
Travere Therapeutics Sees Promising Growth with FILSPARI - AInvest
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Travere Therapeutics (TVTX) Is Up 8.3% After Revenue Jump and Narrower Losses in Q2 – What's Changed - simplywall.st
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics price target raised to $34 from $32 at Citi - MSN
Visual analytics tools that track Travere Therapeutics Inc. performanceFree Low Drawdown Real Time Trading Tips - Newser
Travere Therapeutics Earnings Call Highlights FILSPARI Success - TipRanks
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $32.00 - Defense World
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00 - Defense World
Travere Therapeutics Reports Strong Q2 2025 Growth - MSN
Travere Therapeutics price target raised to $32 from $30 at Wedbush - Yahoo Finance
Travere Therapeutics shares fall 5.16% intraday despite positive earnings report and price target increase. - AInvest
Scotiabank Raises Price Target for Travere Therapeutics (TVTX) t - GuruFocus
Travere Therapeutics: Scotiabank maintains Sector Outperform, PT raised to $31 from $30. - AInvest
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability - simplywall.st
Travere Therapeutics price target raised to $31 from $30 at Scotiabank - TipRanks
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty - Investing.com
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty By Investing.com - Investing.com South Africa
Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating - MarketScreener
TVTX: Wedbush Raises Price Target and Maintains Outperform Ratin - GuruFocus
Travere: Q2 Earnings Snapshot - Huron Daily Tribune
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications - MSN
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts - Investing.com
Travere Therapeutics Reports Second Quarter 2025 Financial Results - BioSpace
Travere Therapeutics: Scaling the Rare Disease Ladder—Can FILSPARI Sustain Its Momentum? - AInvest
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics - AInvest
Transcript : Travere Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Travere Therapeutics 2025 Q2 Earnings Strong Performance with 81.9% Net Loss Reduction - AInvest
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Travere Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):